Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:October 12, 2017
End Date:August 2019

Use our guide to learn which trials are right for you!

1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from
plasma of stage IV cancer patients at HCC.

2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when
available, with those of primary tumor and metastasis.

The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to
determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic
acid. DNA contains information that determines in part the traits, such as eye color, height,
or disease risk, that are passed on from parent to child. This reaction will be measured by
studying patient blood that will be collected before and during treatment until there is
disease progression.

Inclusion Criteria:

- Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors
(including lymphoma)

- Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3

- Life expectancy ≥ 3 months

- Patients must be able to provide consent

- Patients can be enrolled in other interventional clinical trials

Exclusion Criteria:

- Age < 18-year-old
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Antonio Giordano, MD
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials